Analysis of MARIPOSA & SKIPPirr Trials: Safety and Quality of Life
Panelists discuss how targeted cancer therapies, particularly those affecting the EGFR and c-MET receptors, present unique adverse effects such as dermatologic reactions and venous thromboembolism, emphasizing the importance of proactive management, patient education, and evolving treatment strategies to balance efficacy with quality of life.
Video content above is prompted by the following:
Key Findings on EGFR-Targeting Therapies and Associated Adverse Effects
Adverse Effects Profile
- General Toxicities: The use of EGFR-targeting agents, such as cetuximab, in combination with other therapies, leads to a range of toxicities. This includes dermatologic effects, gastrointestinal disturbances, and venous thromboembolism (VTE).
- Skin-Related Effects: While skin toxicity is commonly associated with active vitamin PKIs, it has also been observed with EGFR-targeted kinase inhibitors. There are ongoing efforts to manage dermatologic adverse effects proactively, including treatment of scalp and nail changes.
- VTE: A unique observation in clinical trials was an increased incidence of VTE, which was not initially anticipated. This suggests a specific pharmacologic interaction when combining these agents with other therapies.
Management of Adverse Effects
- Early Recognition and Treatment: Severe toxicities were observed in some patients, emphasizing the need for early intervention and management strategies.
- Anticoagulation Protocol: The trial was amended to include prophylactic anticoagulation for the first 4 months, which has become standard practice. The majority of thrombotic events were observed within this period, reinforcing the need for a structured prevention strategy.
- Prophylactic Skin Care Measures: Investigators have implemented preemptive skin care regimens to mitigate dermatologic toxicities. The study also underscored the importance of standardized education for patients and health care providers regarding dermatologic adverse events.
- Dexamethasone for Immune Reactions: The use of prophylactic dexamethasone 2 days prior to therapy has shown to reduce immune-related reactions significantly, similar to strategies used in prior supportive care studies.
Clinical Considerations for Therapy Optimization
- Experience and Training: Physicians and nurse practitioners require adequate training to manage adverse effects effectively. Institutions should develop treatment pathways and educational resources to ensure consistent care.
- Quality of Life Considerations: Newer formulations, such as subcutaneous options, are showing promise in improving patient convenience and adherence by reducing the number of hospital visits and allowing for home administration.
- Future Directions: Ongoing trials (e.g., the Hubertus trial) are investigating novel formulations and treatment strategies, with preliminary results suggesting improved patient outcomes and tolerability.
Implications for Clinical Practice
- Balancing Toxicity and Efficacy: Increased toxicity often indicates an active drug, but the challenge lies in managing these adverse effects effectively without compromising treatment benefits.
- Lessons From Clinical Trials: The introduction of prophylactic interventions (e.g., anticoagulation and skin care) has demonstrated significant benefits, and similar approaches should be adopted in routine clinical practice.
- Oncology Care Evolution: Steroids remain an essential supportive therapy in oncology, helping manage toxicities and improving patient tolerance to treatment.
Conclusion
Physicians should focus on early detection and management of toxicities associated with EGFR-targeted therapies, particularly dermatologic effects and thromboembolism. The integration of prophylactic interventions and patient education is crucial for optimizing treatment outcomes and maintaining quality of life. The evolution of subcutaneous formulations and structured care pathways will likely improve patient adherence and overall treatment success.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
